Please assess the completion status of the following clinical trial:

Trial Title: Agatolimod and Trastuzumab in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically or cytologically confirmed breast cancer~  * Locally advanced or metastatic disease~* HER2-overexpressing tumor, defined as 3+ overexpression by IHC and/or HER2 amplified by FISH~* Non-measurable disease allowed~* Achieved partial response, complete response, or stable disease (i.e., no disease progression for ≥ 12 weeks) while on trastuzumab (Herceptin®) and chemotherapy, hormonal therapy alone, or trastuzumab alone~  * Last dose of trastuzumab must have been administered within the past 16 weeks~* No unstable brain metastases~  * Patients with brain metastases are eligible provided they have been stable for ≥ 1 month after surgery or radiotherapy/radiosurgery AND off corticosteroids and anticonvulsants for ≥ 4 weeks~* Hormone receptor status unspecified~PATIENT CHARACTERISTICS:~* ECOG(Eastern Cooperative Oncology Group)performance status (PS) 0-2 (Karnofsky PS 70-100%)~* Absolute neutrophil count ≥ 1,500/mm³~* Hemoglobin \> 8 g/dL (transfusion/epoetin alfa allowed)~* Platelet count ≥ 100,000/mm³~* Total bilirubin \< 1.5 times upper limit of normal (ULN)~* AST and ALT ≤ 2.5 times ULN (≤ 5.0 times ULN if known liver metastases)~* Creatinine \< 2 mg/mL~* Ejection fraction ≥ 50% by echocardiogram or MUGA~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception before, during, and for ≥ 3 months after completion of study treatment~* No ongoing or active infection requiring oral or IV antibiotics~* No known autoimmune disorders or antibody-mediated disorders~* No known HIV positivity~* No known history of hepatitis B or C (active and/or previously treated)~* No other malignancies within the past 5 years except nonmelanoma skin cancer or cervical cancer in situ~* No history of allergic reactions attributed to compounds of similar chemical or biologic composition to study drugs~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* More than 12 weeks since prior chloroquine~* More than 4 weeks since prior growth factors~* More than 4 weeks since prior systemic corticosteroids~* More than 4 weeks since prior chemotherapy, radiotherapy, or monoclonal antibody therapy (except trastuzumab)~* No prior agatolimod sodium~* No prior allogeneic stem cell transplantation~* No prior continuous treatment with single-agent trastuzumab for \> 6 months~* No more than 3 prior chemotherapy regimens for metastatic breast cancer~* Any number of prior hormonal therapies allowed~* No other concurrent investigational agents or monoclonal antibodies~* No other concurrent anticancer agents or therapies~* Concurrent bisphosphonates for skeletal metastasis allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I: Treatment (PF03512676 in combination with Trastuzumab) (Type: EXPERIMENTAL): 12 weekly treatments. Week 1-12 patients will receive Trastuzumab 2mg/kg IV(intervenous infusion). Patients who have not been treated wih Trastuzumab within 4 weeks will receive a loading dose of 4 mg/kg on week 1 and PF-03512676-0.16 mg/kg subcutaneous injection.Correlative studies will be drawn on week 1, 2, 6, 12 and 18.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues